- Home
- SANA
as 11-21-2024 4:00pm EST
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 among others.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | SEATTLE |
| Market Cap: | 887.6M | IPO Year: | 2021 |
| Target Price: | $11.50 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.38 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.29 - $12.00 | Next Earning Date: | 11-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Sana Biotechnology Inc. (SANA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Mulligan Richard | SANA | Director | Sep 24 '24 | Sell | $3.99 | 300,000 | $1,195,740.00 | 2,848,121 |
Latest Sana Biotechnology Inc. News
SANA Breaking Stock News: Dive into SANA Ticker-Specific Updates for Smart Investing
Zacks
9 days ago
Here's Why Sana (SANA) Could be Great Choice for a Bottom Fisher
Zacks
11 days ago
Down -24.69% in 4 Weeks, Here's Why Sana (SANA) Looks Ripe for a Turnaround
Associated Press Finance
14 days ago
Sana: Q3 Earnings Snapshot
GlobeNewswire
14 days ago
Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates
MT Newswires
17 days ago
JMP Securities Downgrades Sana Biotechnology to Market Perform
BioPharma Dive
17 days ago
Sana to lay off staff, deepen autoimmune focus in latest retrenchment
GlobeNewswire
17 days ago
Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025
PR Newswire
a month ago
Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence
Compare SANA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SANA Sana Biotechnology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.